Remyelination varies between and within lesions in multiple sclerosis following bexarotene

OBJECTIVE: In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexarotene versus placebo in 49 people with multiple sclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, J. William L., Prados, Ferran, Altmann, Daniel R., Kanber, Baris, Stutters, Jonathan, Cunniffe, Nick G., Jones, Joanne L., Georgieva, Zoya G., Needham, Edward J., Daruwalla, Cyrus, Wheeler‐Kingshott, Claudia Gandini, Connick, Peter, Chandran, Siddharthan, Franklin, Robin, MacManus, David, Samson, Rebecca, Coles, Alasdair, Chard, Declan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539389/
https://www.ncbi.nlm.nih.gov/pubmed/36116011
http://dx.doi.org/10.1002/acn3.51662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539389/
https://www.ncbi.nlm.nih.gov/pubmed/36116011
http://dx.doi.org/10.1002/acn3.51662

Ejemplares similares